Aggressive Lymphome
Indolente Lymphome
Single-Agent Ibrutinib for Rituximab-Refractory Waldenström Macroglobulinemia: Final Analysis of the Substudy of the Phase III InnovateTM Trial.
Trotman J, Buske C, Tedeschi A, Matous JV, MacDonald D, Tam CS, Tournilhac O, Ma S, Treon SP, Oriol A, Ping J, Briso EM, Arango-Hisijara I, Dimopoulos MA.Clin Cancer Res. 2021 Nov 1;27(21):5793-5800.
PMID: 34380643 DOI: 10.1158/1078-0432.CCR-21-1497
Zanubrutinib for the treatment of MYD88 wild-type Waldenström macroglobulinemia: a substudy of the phase 3 ASPEN trial.
Dimopoulos M, Sanz RG, Lee HP, Trneny M, Varettoni M, Opat S, D'Sa S, Owen RG, Cull G, Mulligan S, Czyz J, Castillo JJ, Motta M, Siddiqi T, Gironella Mesa M, Granell Gorrochategui M, Talaulikar D, Zinzani PL, Askari E, Grosicki S, Oriol A, Rule S, Kloczko J, Tedeschi A, Buske C, Leblond V, Trotman J, Chan WY, Michel J, Schneider J, Tan Z, Cohen A, Huang J, Tam CS.Blood Adv. 2020 Dec 8;4(23):6009-6018.
PMID: 33284944 PMCID: PMC7724905 DOI: 10.1182/bloodadvances.2020003010
Mantelzelllymphome
T-Zell-Lymphome
ZNS-Lymphome
Forschung zu COVID-19
Prolonged Course of COVID-19-Associated Pneumonia in a B-Cell Depleted Patient After Rituximab.
Igor Kos, Benedikt Balensiefer, Sophie Roth, Manfred Ahlgrimm, Martina Sester, Tina Schmidt, Lorenz Thurner, Moritz Bewarder, Robert Bals, Frank Lammert, Stephan Stilgenbauer, Dominic Kaddu-Mulindwa. Front Oncol 2020 Sep 2;10:1578.
PMID: 32984017 PMCID: PMC7493633 DOI: 10.3389/fonc.2020.01578
Arbeitsgruppenübergreifende Forschung
Characterization of an HLA-restricted and human cytomegalovirus-specific antibody repertoire with therapeutic potential.
Bewarder M, Held G, Thurner L, Stilgenbauer S, Smola S, Preuss KD, Carbon G, Bette B, Christofyllakis K, Bittenbring JT, Felbel A, Hasse A, Murawski N, Kaddu-Mulindwa D, Neumann F. Cancer Immunol Immunother. 2020 Apr 16.
PMID: 32300857 PMCID: PMC7347513 DOI: 10.1007/s00262-020-02564-1